Our screening made use of tumor challenge as the primary marker of e-mimotope activity, which was justified by the observation that mimotopes that induce high-frequency CD8+ T cells cross-reactive with the native epitope based on tetramer or IFNγ readouts may not optimally recognize the native epitope in the context of MHC-I expressed on cancer cells. The gene discussed is CD8A; the disease is neoplasm.